The inability to produce normal levels of the mitochondrial protein frataxin causes the hereditary degenerative disorder Friedreich's Ataxia (FRDA), a syndrome characterized by progressive gait instability, cardiomyopathy and high incidence of diabetes. Frataxin is an iron-binding protein involved in the biogenesis of iron -sulfur clusters (ISC), prosthetic groups allowing essential cellular functions such as oxidative phosphorylation, enzyme catalysis and gene regulation. Although several evidence suggest that frataxin acts as an iron-chaperone within the mitochondrial compartment, we have recently demonstrated the existence of a functional extramitochondrial pool of mature frataxin in various human cell types. Here, we show that a similar proteolytic process generates both mature mitochondrial and extramitochondrial frataxin. To address the physiological function of human extramitochondrial frataxin, we searched for ISC-dependent interaction partners. We demonstrate that the extramitochondrial form of frataxin directly interacts with cytosolic aconitase/iron regulatory protein-1 (IRP1), a bifunctional protein alternating between an enzymatic and a RNA-binding function through the 'iron -sulfur switch' mechanism. Importantly, we found that the cytosolic aconitase defect and consequent IRP1 activation occurring in FRDA cells are reversed by the action of extramitochondrial frataxin. These results provide new insight into the control of cytosolic aconitase/IRP1 switch and expand current knowledge about the molecular pathogenesis of FRDA.
INTRODUCTION
Frataxin is an iron-binding protein strictly conserved during evolution, from proteobacteria to humans (1) . Although different evidence indicates an involvement of frataxin in intracellular iron homeostasis (2) , the primary function of this protein is still elusive. Frataxin deficiency clearly leads to defective iron-sulfur clusters (ISC) and heme biosynthesis, with further consequences concerning mitochondrial iron overload, impaired mitochondrial respiration, low ATP production, oxidative damage and enhanced stress-induced apoptosis (3) . The ISC-dependent proteins play an essential role in several aspects of cellular metabolism including respiratory electron transfer, enzyme catalysis and DNA repair (4, 5) . Studies in yeast models have shown that biogenesis of ISC requires a large number of proteins catalyzing the process (4) . The central components are those involved in transient assembly of ISC on a scaffold protein, within mitochondria. Isu1/ ISCU acts as scaffold protein in all eukaryotes (6) . The cysteine desulfurase Nfs1/ISCS provides the sulfur moiety, together with the Isd11 protein (7, 8) . Although the source of iron to synthesize ISC is less well defined, several data support the notion that frataxin is the iron donor of the reaction (9, 10) . In yeast, ISC biosynthesis seems to occur exclusively in the mitochondria. This hypothesis implies that mitochondria are indispensable to build all cellular ISC proteins, leading to the proposal that the preformed ISC are transported outside mitochondria by the ISC export machinery and finally inserted in extramitochondrial targets by the cytosolic ISC assembly (CIA) machinery (4) . Little is known about the extramitochondrial ISC biogenesis in mammalian cells. Homologues of the yeast proteins involved in export and cytosolic assembly exist and are functional in humans (11) (12) (13) . Moreover, extramitochondrial isoforms of the central components ISCU (14) , NFU (15) and ISCS (16) have been identified in human cells.
Thus, mammalian biogenesis of extramitochondrial ISC shows partial similarity with the yeast's model, but nevertheless the pathways may be specified by fundamental distinctions.
In humans, a paradigm for frataxin defect is the degenerative disorder Friedreich's ataxia (FRDA) . FRDA is an autosomal recessive monogenic disease characterized by progressive gait instability, loss of coordination, hypertrophic cardiomyopathy and increased incidence of diabetes mellitus (17) . In almost all of the patients (95 -98%), this disorder is caused by the homozygous hyperexpansion of a GAA-triplet repeat within the first intron of the FXN gene (18) , a condition that results in lowered expression of the encoded frataxin protein (19) . Human frataxin is synthesized as a 23 kDa precursor protein, which needs N-terminal proteolytic processing within the mitochondria to be converted into the functional mature form (20) . Although initially considered a protein exclusively confined to the mitochondrial matrix (19) , we and others recently demonstrated the existence of an extramitochondrial pool of mature frataxin in different human cell types (21 -23) . Extramitochondrial frataxin is a functionally relevant protein, since its expression directly suppresses apoptosis in transformed cell lines and protects FRDA patients' lymphoblasts from stress-induced cell death (22) . A growing body of evidence indicates that mitochondrial frataxin acts as an iron-chaperone by providing ferrous iron (Fe 2þ ) in a bioavailable form. In vitro and in vivo studies proved that frataxin interacts with several proteins involved in the biogenesis of ISC: the scaffold ISCU/Isu1 (9, 24) , the chaperone GRP75 (25) and the adaptor protein ISD11 (25) . Moreover, mitochondrial frataxin physically binds the ISC-containing enzymes ferrochelatase (26) , succinate dehydrogenase (27) and mitochondrial aconitase (28, 29) . The direct interaction with ISCdependent proteins reveals an additional role for frataxin in modulating the activity of its partners, as demonstrated by the protection/reactivation of mitochondrial aconitase (28) .
In this study, we provide evidence for a physiological role of extramitochondrial frataxin in the cytoplasmic compartment. We first characterized the amino terminus of extramitochondrial frataxin generated in human cells. Our results indicate that the extramitochondrial frataxin matches the mature mitochondrial frataxin. Moreover, using a co-immunoprecipitation approach, we found that extramitochondrial frataxin directly interacts with the ISC-dependent cytosolic aconitase/iron regulatory protein-1 (IRP1) bifunctional protein. Importantly, we demonstrate that the cytosolic aconitase defect and consequent IRP1 activation in FRDA patients' cells can be reverted by extramitochondrial frataxin. Our findings suggest a direct function of frataxin in the regulation of cytosolic aconitase/IRP1 activity.
RESULTS

Mitochondrial processing generates the extramitochondrial frataxin
We previously reported that expression in human cells of wildtype frataxin cDNA (frataxin 1 -210 , FXN 1 -210 ), encoding the 210 aminoacid precursor protein, generated a mature product that not only localized within mitochondria but also in the cytoplasm (22) . This subcellular distribution is independent of forced expression, because endogenous extramitochondrial frataxin is detectable in primary cells as well as in tumor cell lines (21 -23) . To better characterize extramitochondrial frataxin, we took advantage of the Flp-In-293 cells stably expressing FXN 1 -210 previously described (20) (Fig. 1A , left panel). The stable expression of FXN 1 -210 results mainly in accumulation of the mature mitochondrial product, generated by a proteolytic cleavage between Lys80 and Ser81 (FXN 81 -210 ; 20). Furthermore, subcellular fractionations showed the presence of the extramitochondrial form in the cytosolic fractions prepared from the above cells (20) . HEK-293 cells stably expressing FXN 1 -210 were then used to identify the N-terminus of the extramitochondrial frataxin. To this end, highly purified cytosolic fractions were prepared and checked by western blot analysis. The mature frataxin recovered from mitochondrial fractions comigrates with the extramitochondrial form obtained from cytosolic fractions ( Fig. 1A , right panel). To rule out cross-contamination of fractions, mitochondrial matrix MnSOD and cytosoplasmic tubulin were used as controls. The purity of subcellular fractions was further confirmed by the analysis of additional mitochondrial and cytosolic markers (Supplementary Material, Fig. S1 ). Frataxin was immunoprecipitated from the above cytosolic fractions, resolved on SDS -PAGE and subjected to sequential Edman degradation. As summarized in Figure 1B the N-terminal sequence obtained was S-G-T-L-G-H, corresponding to the same residues previously identified in the N-terminus of mature frataxin generated 
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Human Molecular Genetics, 2010, Vol. 19, No. 7 upon mitochondrial processing. Together, these results indicate that the extramitochondrial protein is a FXN 81 -210 polypeptide and that a similar proteolytic processing accounts for both mature mitochondrial and extramitochondrial frataxin.
Extramitochondrial frataxin physically interacts with the cytosolic aconitase/IRP1 protein To address the physiological function of extramitochondrial frataxin, we investigated its involvement in regulation of cytosolic ISC. To this purpose, we searched for interaction partners of extramitochondrial frataxin in human cells. Given the ability of mitochondrial frataxin to act as an iron-chaperone that interacts with mitochondrial aconitase by modulating its ISCdependent enzyme activity, we reasoned that a corresponding interaction between their cytosolic counterparts could be possible. To determine if extramitochondrial frataxin and cytosolic aconitase/IRP1 share the same subcellular localization, HEK-293 cells were transiently transfected with extramitochondrial FXN 81 -210 together with a Myc-tagged IRP1 (Myc-IRP1) and analyzed by immunofluorescence microscopy. As expected, both proteins were predominantly located in the cytoplasm. The merged images demonstrate their co-localization as revealed by the yellow areas ( Fig. 2A ). To test for the possible interaction between extramitochondrial frataxin and cytosolic aconitase/ IRP1, we carried out a co-immunoprecipitation approach. HEK-293 cells were transiently transfected with either empty vector (EV), FXN 1 -210 or extramitochondrial FXN 81 -210 together with Myc-IRP1. In order to avoid artefactual interactions caused by excessive overexpression of Myc-IRP1, HEK-293 cells were transfected with amounts of the corresponding construct leading to moderated expression levels (Supplementary Material, Fig. S2 ). Cell extracts from transfected cells were immunoprecipitated with anti-frataxin mAb, and anti-Myc immunoblot analysis demonstrated the co-purification of Myc-IRP1 ( Fig. 2B ). Conversely, immunoprecipitation of Myc-IRP1 with anti-Myc resulted in co-purification of frataxin, as detected by anti-frataxin immunoblot analysis ( Fig. 2C ). In neither case negative control for immunoprecipitations with an irrelevant isotype-matching antibody or without antibody allowed detection of the above proteins ( Fig. 2D ). Notably, in both cases the interaction is evident in the absence of frataxin overexpression, demonstrating that endogenous extramitochondrial frataxin is sufficient to bind transfected Myc-IRP1. The interaction is slightly increased in FXN 1 -210 -transfected cells and it is strongly enhanced in the presence of transfected frataxin 81 -210 (FXN 81 -210 ). To further characterize the interaction, we examined if the binding between FXN 81 -210 and cytosolic aconitase is modulated by the presence of enzyme's ISC. We generated a mutant protein (IRP1 C437S) lacking a critical cysteine responsible for coordination of the cluster. This mutant lacks aconitase activity and displays only the RNAbinding activity (30, 31) . As shown in Figure 3 , immunoprecipitation and immunoblot analysis in both directions demonstrate that the presence of C437S substitution in IRP1 strongly inhibited the interaction with extramitochondrial frataxin. These data collectively demonstrate that FXN 81 -210 can directly interact with cytosolic aconitase/IRP1 in the extramitochondrial compartment.
Extramitochondrial frataxin rescues the cytosolic aconitase activity
As known, reduced frataxin expression determines a contemporary loss in activity of mitochondrial and cytosolic aconitases (32, 33) , two ISC-requiring enzymes encoded by two different genes (34) . To investigate the functional implications of the interaction between extramitochondrial frataxin and cytosolic aconitase/IRP1, we looked for a functional relationship between frataxin localization and aconitase activity. To this purpose, frataxin-deficient lymphoblasts derived from a FRDA patient were stably reconstituted with either an EV, FXN 1 -210 or extramitochondrial FXN 81 -210 ( Fig. 4A ) and total and subcellular protein extracts were assayed for aconitase activity. To evaluate the status of both aconitases, two independent activity assays were used. Enzyme activity was monitored both in subcellular fractions, by spectrophotometric analysis (Fig. 4B and C), and in total lysates, by native in-gel assays ( Fig. 5 ). As expected, both mitochondrial and cytosolic extracts from FRDA lymphoblasts show a significant deficit of aconitase activity with respect to control lymphoblasts derived from an healthy brother of the patient (Figs 4 and 5 ). Mitochondrial aconitase is rescued in FRDA cells reconstituted with FXN 1 -210 but could not be significantly restored in FRDA cells reconstituted with FXN 81 -210 (Figs 4B and 5B). On the other hand, although cytosolic aconitase is rescued in FRDA cells reconstituted with FXN 1 -210 , it is even more efficiently rescued in FRDA cells reconstituted with FXN 81 -210 . The in-gel assay fully confirmed this finding ( Fig. 5 ). Furthermore, since the native in-gel assay allows the simultaneous visualization of both activities, we could quantitate the relative contribution of the cytosolic enzyme with respect to the total aconitase activity. We calculated that the cytosolic aconitase represents 16% of total cellular aconitase activity in EV-reconstituted FRDA lymphoblasts. The simultaneous effect on the activity of both isozymes did not significantly change this proportion in FXN 1 -210 -reconstituted FRDA cells, whereas the reconstitution with FXN 81 -210 raised the percent of the cytosolic activity to 30% of total, mostly due to a specific boost of the cytosolic enzyme ( Fig. 5B) . These results suggest that extramitochondrial frataxin can directly affect the enzymatic activity of cytosolic aconitase.
Extramitochondrial frataxin modulates the RNA-binding activity of IRP1
The enzymatic activity of cytosolic aconitase and the RNAbinding activity of IRP1 are two mutually exclusive functions of the same protein. The presence of a 4Fe -4S cluster allows its enzymatic function as aconitase, whereas a complete loss of this cofactor triggers its mRNA-binding ability (35) . We thus analyzed FRDA lymphoblasts for the iron responsive element (IRE)-binding ability of IRP1. As previously reported for FRDA patient cells (36, 37) , as well as for a human cell model of frataxin depletion (33), we found that FRDA lymphoblasts showed increased IRP1 activity compared with their healthy control (Fig. 6A ). RNA band-shift analysis indicates a strong increase of IRPs-binding activity without any variation of IRP1 expression levels between FRDA and control cells, as judged by in vitro b-mercaptoethanol activation and by western blot studies (Fig. 6A ). In this band-shift assay human IRP1 and IRP2 comigrate. IRP2 is another IREbinding protein which is not an ISC-dependent protein and 
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Human Molecular Genetics, 2010, Vol. 19, No. 7 whose activity is regulated through protein degradation. To exclude a contribution of IRP2, protein expression level was therefore analyzed in control and FRDA cells. Western blot analysis revealed equal levels of IRP2, thus confirming an exclusive activation of IRP1-binding activity in the above FRDA lymphoblasts (Fig. 6A) . We then performed experiments to examine the effects of extramitochondrial frataxin on IRP1 activation. Extracts from FRDA cells stably reconstituted with either EV, FXN 1 -210 or FXN 81 -210 were analyzed by RNA band-shift and western blotting (Fig. 6B ). RNA band-shift showed a marked reduction of IRPs-binding activity in FXN 1 -
210
-reconstituted FRDA cells compared with corresponding EV-reconstituted FRDA cells (Fig. 6B ). This effect is indistinguishable from that observed in FXN 81 -210 -reconstituted FRDA cells (Fig. 6B) , demonstrating the specific action of extramitochondrial frataxin on IRP1 status. The reduced IRPs activity cannot be accounted by altered IRP1 expression levels, as judged by in vitro b-mercaptoethanol activation and by western blot studies (Fig. 6B) , consistent with the fact that extramitochondrial frataxin functionally converts IRP1 to its cytosolic aconitase form. Moreover, western blots confirmed that IRP2 protein levels were not altered (Fig. 6B) , ruling out a contribution by IRP2. Collectively, the data indicate that the extramitochondrial form of human frataxin plays a critical function in the cytosolic aconitase/IRP1 switch.
DISCUSSION
In the past few years, the understanding of the function of frataxin has grown rapidly (3). Consequently, pathophysiological defects of FRDA have become more comprehensible, thus allowing the design of new therapeutic approaches (38 -40) . However, the molecular function of this protein was investigated mainly with respect to mitochondrial physiology. Subcellular localization of frataxin in mammalian cells is currently under debate. Recently, an extramitochondrial pool of mature frataxin was detected in several cell types of human origin (21 -23) . We demonstrated that overexpression of extramitochondrial frataxin confers protection against stress-induced apoptosis in frataxin-deficient cells (22) . Moreover, forced expression of wild-type frataxin precursor in different cell lines leads to a substantial production of a frataxin form that does not reside in the mitochondrial compartment (20, 22) . Strikingly, in the microsporidian parasite Trichomonas hominis, which has mitosomes instead of mitochondria, the main pool of frataxin is located in the cytosol (41) . In contrast to the mitochondrial frataxin, very little is known about biogenesis and function of extramitochondrial frataxin. A recent analysis of the mitochondrial maturation process allowed us to identify for the first time the 14 kDa active form of mature frataxin generated in human living cells (20) . In the present study, we have made an effort to characterize the mature extramitochondrial form. Edman degradation of extramitochondrial frataxin purified from living cells indicates that this form has an amino terminus starting with Ser81. The N-terminal sequence obtained corresponds to that previously identified in the N-terminus of mature frataxin generated upon mitochondrial processing (20) . These results demonstrate that both mitochondrial and extramitochondrial isoforms are identical FXN 81 -210 polypeptides. Thus, our data support a view in which mature FXN 81 -210 is first produced by a two-step mitochondrial proteolytic process and then it is partially exported outside the mitochondria by a still unknown mechanism. The multiple distribution of a protein between subcellular compartments usually arises from multiple transcription start sites, alternative splicing or different translation initiations (42) . On the contrary, the notion that mature mitochondrial and extramitochondrial frataxin are identical is reminiscent of the dual targeting of yeast fumarase enzyme (43) . Similarly to frataxin, the fumarase precursor is directed to mitochondria and matured by mitochondrial processing peptidase. A subset of mature fumarase is then imported into the matrix, whereas another part is released in the cytosol by retrograde movement through the translocation pore (44) . As a result of such mechanism, mitochondrial and cytosolic forms of yeast fumarase share identical N-termini (45) .
To investigate the metabolic role of extramitochondrial frataxin, we sought to identify its cytosolic targets. Mitochondrial frataxin is a double-side modulator of mitochondrial aconitase activity. First, the role of frataxin in the biosynthesis of ISC impacts on cellular availability of prosthetic group required for enzyme's function (32, 33) . Second, frataxin directly chaperones Fe 2þ to the inactive 3Fe-4S cluster of mitochondrial aconitase in order to reconstitute a functional 4Fe -4S cluster (28) . Two distinct genes encode mammalian mitochondrial and cytosolic aconitases. Both proteins require a 4Fe-4S cluster for enzymatic activity. Moreover, the two aconitases share 30% overall identity, showing a striking overlap of active site residues (46) . By co-expression in HEK-293 cells, we demonstrate that extramitochondrial frataxin co-localizes and interacts with cytosolic aconitase/IRP1 protein. Immunoprecipitation of transfected frataxin results in co-precipitation of transfected IRP1, and this is confirmed by the reverse approach. Strikingly, physical association between the two proteins is evident without a forced expression of extramitochondrial frataxin. This provides additional evidence that human cells express a functional endogenous frataxin in the cytoplasm. Moreover, we report that such interaction is largely, although not exclusively, dependent on the presence of an ISC inserted into the cytosolic aconitase form. Through the so-called 'ISC-switch' cytosolic aconitase/IRP1 alternates between two mutually exclusive functions: the ISCcontaining form is an enzyme converting cytosolic citrate to isocitrate, whereas the ISC-devoid form regulates gene expression by the binding to specific mRNA targets (35) . The defective activity of mitochondrial and cytosolic aconitases, as well as an increased IRP1 RNA-binding activity, are clearly associated with frataxin deficiency in model organisms (47) (48) (49) , in human cell cultures (23, 33) and in patients affected by FRDA (32, 36, 37) . We looked for a compartmentspecific function of frataxin on aconitases activity. Our results indicate that expression of FXN 1 -210 in FRDA cells rescues the activity of both mitochondrial and cytosolic aconitases. Moreover, IRP1 activity returns to basal levels. Conversely, expression of FXN 81 -210 impacts on IRP1-binding ability and activates the cytosolic aconitase, without an evident effect on the mitochondrial one. Given that FRDA cells show a localization of frataxin in both compartments when reconstituted with FXN 1 -210 (Fig. 3A) , the above data strongly suggest a compartment-specific role for frataxin forms. Accordingly, cytosolic aconitase activity was described to decline in parallel with cytosolic frataxin depletion, with no significant deficit in mitochondrial aconitase activity, until depletion of the mitochondrial frataxin pool (23) .
In view of the physical interaction between extramitochondrial frataxin and cytosolic aconitase/IRP1, protection or reactivation of enzyme's ISC represents a major hypothesis for the cytosolic function of frataxin. The molecular mechanisms by which cytosolic aconitase is converted to its IRE binding form are still enigmatic. The 4Fe-4S cluster of cytosolic aconitase is highly sensitive to reactive oxygen species and reactive nitrogen species (50) . These perturbants lead to loss of the labile Fe a atom by generating a transient 3Fe -4S cluster (51 -53) , followed by a complete removal of covalent linkages between aconitase and its cofactor (54) . The protein containing a 3Fe -4S cluster was reported to possess neither enzyme activity nor RNA binding activity; however, it can be reverted to the aconitase form by Fe 2þ supply (51) . As recently demonstrated (55) , the equilibrium of cycling between 4Fe -4S and 3Fe-4S seems critical for conversion to the RNA binding form. Because oxidative stress endogenously occurs in FRDA cells, cytosolic aconitase deficit and IRP1 activation are ascribed, at least in part, to an excessive ISC damage. Thus, although not directly addressed by this work, extramitochondrial frataxin could impact on the 3Fe -4Fe equilibrium by direct delivery of Fe 2þ to damaged 3Fe -4S cluster of cytosolic aconitase. Moreover, a more general role in biogenesis of cytosolic ISC cannot be excluded and will require further investigations. In this regard, extramitochondrial frataxin was described to interact with the cytosolic isoform of ISCU (cISCU or ISCU1) (21), a scaffold protein for ISC biosynthesis. The isoform specific depletion of human mitochondrial and cytosolic ISCU provided evidence for a selective function in their respective compartments (14) . Although silencing of cISCU resulted in only slight changes in the steady-state activity of cytosolic aconitase, the impact on ISC repair/regeneration toward this enzyme is strongly evident (14) . In addition, two recently identified homologues of the yeast CIA machinery were involved in maturation of cytosolic ISC in mammals. As a result, RNAi knockdown of IOP1 (12; homologue of yeast Nar1) or huNbp35/Nubp1 (13; homologue of yeast Nbp35) impairs activity of cytosolic aconitase and activates IRP1-binding ability, whereas mitochondrial aconitase remains intact.
Results presented here provide the first evidence on the molecular control of cytosolic aconitase/IRP1 activity by extramitochondrial frataxin. These data propose an extramitochondrial role for frataxin in the emerging pathways governing cytosolic ISC-dependent proteins in humans and contribute to a better understanding of molecular pathophysiology of FRDA.
MATERIALS AND METHODS
cDNA expression constructs and cell transfections
The pIRES2/FXN 1 -210 , pIRES2/FXN 81 -210 and pcDNA3/ FXN 81-210 constructs were described elsewhere (20) . Human
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Human Molecular Genetics, 2010, Vol. 19, No. 7 IRP1 cDNA containing XhoI site at 5 0 -end/XbaI at 3 0 -end was obtained by PCR from the clone MGC-8709 (ATCC) and inserted in pcDNA3Myc vector to express an N-terminal Myc-IRP1 protein. The mutant construct pcDNA3Myc/ IRP1 C437S was generated using the QuickChange site-directed mutagenesis kit (Stratagene) using pcDNA3Myc/IRP1 as template. All final constructs were verified by sequencing. GM15850B lymphoblasts, from a clinically affected FRDA patient and GM15851B lymphoblasts from a clinically unaffected brother of GM15850 were obtained from NIGMS Human Genetic Cell Repository, Coriell Institute for Medical Research. FRDA lymphoblasts were stably transfected by electroporation and selected with 500 mg/ml G418 (Invitrogen) as reported (20) . Human embryonic kidney HEK-293 cells were transiently transfected with 20 mg total DNA using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions.
Subcellular fractionations
Mitochondrial and cytosolic extracts were prepared as previously described (22) 
Immunoprecipitation and western blotting
Cell extracts from HEK-293 cells transiently co-transfected with frataxin and Myc-IRP1 constructs were used to immunoprecipitate either frataxin by mAb anti-frataxin MAB-10876, or Myc-IRP1 by mAb anti-human c-myc 9E10 (554205 BD Pharmingen). Immunoprecipitates were separated by 12% SDS-PAGE, transferred on Protran nitrocellulose membranes (Whatman) and analyzed by immunoblotting using ECL system detection (GE Healthcare Life Sciences). To analyze total protein extracts, cells were lysed in ice-cold RIPA buffer supplemented with Complete protease inhibitor cocktail. Cell extracts were separated by 12 or 15% SDS-PAGE and immunoblotted with the following antibodies: mAb anti-frataxin (MAB-10876 Immunological Sciences), mAb anti-a-Tubulin (Sigma), anti-MnSOD (StressGen), mAb anti-c-myc 9E10 (BD Pharmingen), anti-IRP1 N-17 (sc-14216 Santa Cruz Biotechnology) and mAb anti-IRP2 7H6 (sc-33682 Santa Cruz Biotechnology).
Aconitase assays
Aconitase activity was measured spectrophotometrically at 340 nm by a coupled reaction of aconitase and isocitrate dehydrogenase. The assay reactions contained 50-100 mg of subcellular fractions in 50 mM Hepes pH 7.4, 1 mM sodium citrate, 0.6 mM MnCl 2 , 0.2 mM NADP þ and 2 U/ml isocitrate dehydrogenase from porcine heart (Sigma-Aldrich). For the calculation of the activities, 1 milliunit of enzyme was defined as the amount of protein that converted 1 nmol of NADP þ in 1 min at 258C. The aconitase in-gel assay was performed as described (14) . Briefly, 100 mg of total extracts from cells lysed in CelLytic M buffer (Sigma-Aldrich) with Complete cocktail were resolved in a 4% stacking, 8% separating gel by electrophoretic run at 18 V/cm for 3.5 h at 48C. Densitometric quantitation was obtained using ImageJ software.
Statistical analysis was performed using a Student's t-test; all values are expressed as means + SD.
IRPs RNA band-shift (RNA EMSA)
The probe used was a 32-mer RNA oligonucleotide corresponding to IRE sequence from human H-ferritin gene (5 0 -GGU UUC CUG CUU CAA CAG UGC UUG GAC GGA AC-3 0 ), labeled with a biotin molecule at 5 0 end (Metabion International AG). Cell lysates were prepared in CelLytic M buffer supplemented with Complete cocktail. Binding reaction contained 5 -10 mg of total extracts in a final volume of 15 -20 ml containing 10 mM Hepes pH 7.4, 40 mM KCl, 3 mM MgCl 2 and 5% glycerol. When needed, b-mercaptoethanol was included to a final concentration of 3% in order to fully activate IRP1-binding ability. After incubation at RT for 10 min, RNAse T1 (Sigma-Aldrich) was added for 10 min, followed by addition of 5 mg/ml heparin (Sigma-Aldrich) for another 10 min, both at RT. Binding reactions were separated by a 6% native PAGE in TBE 0.3X at 16 V/cm for 2 h at RT, transferred on Biodyne B Nylon Membranes (Pierce) and detected using Chemiluminescent Nucleic Acid Detection Module (Pierce).
